The first stop for professional medicines advice

Biosimilars

32 results

Applied filters

Preparing to use ranibizumab biosimilar

5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team

The licence and supporting evidence for ranibizumab biosimilars

5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence

Biosimilar and key generic medicines – December 2025 update

10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.

Primary care discussions: biosimilar insulin

30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
Registration required

The licence and supporting evidence for aflibercept biosimilars

26 September 2025Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences.

The licence and supporting evidence for omalizumab biosimilar

19 September 2025We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).

Preparing to use omalizumab biosimilar

19 September 2025Omalizumab biosimilars are expected soon. We offer general information and implementation advice.

Preparing to use denosumab 60mg biosimilar

11 August 2025Biosimilars of denosumab 60mg (Prolia) are expected soon. We offer general information and implementation advice.

Preparing to use denosumab 120mg biosimilar

11 August 2025Biosimilars of denosumab 120mg (Xgeva) are expected soon. We offer general information and implementation advice.

Understanding biological and biosimilar medicines

1 August 2025Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions